Kiwi you bring up a point worth thinking about. Actually worth finding out how precisely investigators will monitor and collect data from trial participants.
In Mitigate, all participants are Kaiser patients so I assume they should be able to assess them relatively easily. But here is a paragraph from ClinicalTrials:
“Patients randomly assigned and enrolled into the intervention arm will be asked to take IPE (2 grams by mouth twice daily) for a minimum of 6 months and until study completion. Patients assigned to the control arm (i.e., usual care) will be passively followed only electronically via the electronic health record (EHR).”
When reading that I am not precisely clear how Kaiser is following the intervention arm as it sounds it will be a little different from the control arm (passively electronically).
I wrote this on my damn phone so I guess the formatting will be all squished.
News 
Market Data 
Discover 
AI
